Evaluation of ERG responsive proteome in prostate cancer.

ABSTRACT:

Background

Gene fusion between TMPRSS2 promoter and the ERG proto-oncogene is a major genomic alteration found in over half of prostate cancers (CaP), which leads to aberrant androgen dependent ERG expression. Despite extensive analysis for the biological functions of ERG in CaP, there is no systematic evaluation of the ERG responsive proteome (ERP). ERP has the potential to define new biomarkers and therapeutic targets for prostate tumors stratified by ERG expression.

Methods

Global proteome analysis was performed by using ERG (+) and ERG (-) CaP cells isolated by ERG immunohistochemistry defined laser capture microdissection and by using TMPRSS2-ERG positive VCaP cells treated with ERG and control siRNA.

Results

We identified 1,196 and 2,190 unique proteins stratifi

SUBMITTER: Tan SH 

PROVIDER: S-EPMC4075339 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature